Overview

Desidustat in the Treatment of Anemia in CKD on Dialysis Patients

Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
A phase 3, multicenter, open-label, randomized, active-controlled study to evaluate the efficacy and safety of Desidustat Tablet versus Epoetin alfa Injection for the treatment of anemia in patients with CKD on dialysis. (DREAM-D)
Phase:
Phase 3
Details
Lead Sponsor:
Cadila Healthcare Limited
Treatments:
Epoetin Alfa